Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mar

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Can Viral Respiratory Infections Increase Lung Cancer Risk

Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males

Early Study Evaluates Two-Vaccine Strategy in T-Cell Lymphoma

Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy

Risk of Breast Cancer After Ovarian Cancer in Women With BRCA1/2 Variants